Abstract
The organ-specific mutagenicity of azathioprine was examined by means of the intrasanguineous host-mediated assay in mice, combined with the D7 strain of Saccharomyces cerevisiae. To assay for changes in the frequency of mitotic gene conversion, mitotic crossing-over and point reverse mutation frequency, a single i.p. dose of azathioprine was administered. Kidney-mediated mutagenicity was significantly enhanced. The ability of liver, kidney and lung S9 fractions (from Na-phenobarbital + beta-naphthoflavone induced mice) to activate azathioprine into genotoxic intermediates was also evaluated in vitro by incubating organ homogenates with S. cerevisiae cells as a target organism. Organ-specific activation was demonstrated only in the liver. The relative role of liver metabolism in the induction of mutations and tumor induction was investigated in in vivo experiments with partially hepatectomized mice. The data demonstrated that liver affects both kidney- and lung-mediated mutagenicity and indicated that hepatic metabolism can contribute mutagenic metabolites for cancer initiation by azathioprine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
